Your browser doesn't support javascript.
loading
Identifying potential anti-COVID-19 pharmacological components of traditional Chinese medicine Lianhuaqingwen capsule based on human exposure and ACE2 biochromatography screening
Acta Pharmaceutica Sinica B ; (6): 222-236, 2021.
Article in English | WPRIM | ID: wpr-881092
ABSTRACT
Lianhuaqingwen (LHQW) capsule, a herb medicine product, has been clinically proved to be effective in coronavirus disease 2019 (COVID-19) pneumonia treatment. However, human exposure to LHQW components and their pharmacological effects remain largely unknown. Hence, this study aimed to determine human exposure to LHQW components and their anti-COVID-19 pharmacological activities. Analysis of LHQW component profiles in human plasma and urine after repeated therapeutic dosing was conducted using a combination of HRMS and an untargeted data-mining approach, leading to detection of 132 LHQW prototype and metabolite components, which were absorbed

Full text: Available Index: WPRIM (Western Pacific) Type of study: Diagnostic study / Screening study Language: English Journal: Acta Pharmaceutica Sinica B Year: 2021 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Type of study: Diagnostic study / Screening study Language: English Journal: Acta Pharmaceutica Sinica B Year: 2021 Type: Article